{"filings":[{"id":1176358,"accession_number":"0001213900-26-070316","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2026-06-22T10:05:49+00:00","items":["5.07"],"status":"ready","headline":"Unicycive stockholders re-elect three directors and ratify auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors elected: Dr. Shalabh Gupta (8.13M for, 174k withhold), Dr. Sandeep Laumas (7.70M for, 610k withhold), D. Sarawati Kenkare-Mitra (7.51M for, 795k withhold).","Ratification of Grassi & Co. as auditor for FY 2026 passed with 14.67M for, 287k against, 10k abstentions.","14,964,159 shares represented at the meeting, constituting a quorum.","Broker non-votes totaled approximately 6.66M shares on each director election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":888716,"accession_number":"0001213900-26-065828","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2026-06-05T20:19:29+00:00","items":["1.01","9.01"],"status":"ready","headline":"Unicycive raises ATM capacity to $150M; files new $50M shelf registration","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Amendment No. 2 to Sales Agreement with Guggenheim Securities on June 5, 2026.","ATM offering capacity increased from $100M to $150M in aggregate offering price.","Also filed a new S-3 registration statement to sell an additional $50M of common stock.","Previous agreements: initial Sales Agreement Nov 13, 2024; Amendment No. 1 Nov 14, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22641,"accession_number":"0001213900-26-054736","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2026-05-12T11:51:50+00:00","items":["2.02","9.01"],"status":"ready","headline":"Unicycive Q1 2026 net loss $12.8M; OLC PDUFA target June 29, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.8M ($0.54 per share basic/diluted) vs net income of $0.5M in Q1 2025.","Cash, cash equivalents & marketable securities $57.1M as of May 11, 2026; funds operations into 2027.","FDA PDUFA target action date for oxylanthanum carbonate NDA resubmission is June 29, 2026.","R&D expenses down to $1.6M (from $2.2M); G&A up to $6.8M (from $5.8M) year-over-year.","Commercial readiness activities ongoing for potential OLC launch after PDUFA."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95279,"accession_number":"0001213900-26-040179","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Gaurav Aggarwal resigns from Unicycive board effective April 6","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gaurav Aggarwal resigned from the Board of Directors on April 6, 2026.","Resignation was not due to any disagreement with the Company or management.","Company expressed gratitude for Dr. Aggarwal's service on the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108222,"accession_number":"0001213900-26-035961","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Unicycive Therapeutics FY2025 net loss $26.6M ($1.67/sh); OLC PDUFA date June 29, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to common holders: $26.6M ($1.67/sh) vs $37.8M ($5.65/sh) in FY2024.","Cash, equivalents, securities $54.9M as of March 30, 2026; runway into 2027.","FDA accepted OLC NDA resubmission; PDUFA target action date June 29, 2026.","R&D expenses $9.1M (down from $20.0M); G&A $20.4M (up from $12.1M) due to commercial prep.","Commercial readiness for potential OLC launch in 3Q26 ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124661,"accession_number":"0001213900-25-111045","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Unicycive Therapeutics increases ATM offering capacity from $50M to $100M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 1 to Sales Agreement raises aggregate offering price limit from $50M to $100M.","Sales agent remains Guggenheim Securities, LLC; shares sold at market prices under Rule 415.","Company filed a prospectus supplement with the SEC on November 14, 2025, covering the increase.","Legal opinion on share validity from Sheppard Mullin filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124660,"accession_number":"0001213900-25-108847","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Unicycive Q3 net loss $6.0M, cash $42.7M; plans OLC NDA resubmission by year-end 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.0M for Q3 2025 vs $4.1M in Q3 2024; cash $42.7M as of Sept 30, 2025, with runway into 2027.","On track to resubmit NDA for oxylanthanum carbonate (OLC) by year-end 2025 after positive FDA Type A meeting; potential PDUFA in H1 2026.","Presented OLC data at ASN Kidney Week showing 7x reduction in pill volume and 2x reduction in pill count vs current binders.","R&D expenses flat at $3.0M; G&A increased to $4.4M from $3.2M due to higher labor and consulting costs."],"consensus_eps_estimate":-0.5678,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124659,"accession_number":"0001213900-25-102790","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Unicycive expects to resubmit OLC NDA by year-end after constructive FDA Type A meeting; cash $42M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Cash and cash equivalents ~$42M as of Sept 30, 2025; runway into 2027 supports NDA resubmission, potential FDA approval, and launch.","FDA Type A meeting resolved single CRL deficiency re: third-party manufacturing vendor compliance; no other concerns identified.","Company plans to resubmit NDA for Oxylanthanum Carbonate (OLC) before year-end; potential PDUFA date in H1 2026.","FDA confirmed no issues with pre-clinical, clinical, or safety data submitted in original NDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141351,"accession_number":"0001213900-25-077937","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Unicycive discloses securities class action over phosphate binder NDA statements","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Lawsuit filed in U.S. District Court for Northern District of California against company and certain officers.","Alleges violations of federal securities laws regarding public statements on NDA for oxylanthanum carbonate phosphate binder.","Product targets hyperphosphatemia in chronic kidney disease patients on dialysis.","Company believes claims are meritless and intends to vigorously defend the lawsuit.","Lawsuit became known to company on August 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141350,"accession_number":"0001213900-25-077497","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Unicycive sells 3.55M shares for ~$16.3M net via ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 3,549,846 shares at average $4.56 per share since June 30, 2025.","Net proceeds after fees approximately $16.3 million.","Sales executed under November 2024 sales agreement with Guggenheim Securities.","Stock trades on Nasdaq Capital Market under ticker UNCY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141349,"accession_number":"0001213900-25-076066","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Unicycive Q2 net loss $6.4M; requests FDA Type A meeting for CRL on OLC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.4M vs net income of $3.0M in Q2 2024; R&D expenses down to $1.8M.","Cash and equivalents $22.3M as of June 30, 2025; runway expected into H2 2026.","Type A meeting requested with FDA to resolve CRL for oxylanthanum carbonate (OLC).","Pivotal OLC data published in CJASN: >90% patients achieved phosphate control with low pill burden."],"consensus_eps_estimate":-0.7548,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141348,"accession_number":"0001213900-25-061936","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Unicycive regains Nasdaq minimum bid price compliance after reverse split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Regained compliance with Nasdaq minimum bid price of $1.00 per share.","Nasdaq notified the company on July 7, 2025, confirming compliance as of July 3, 2025.","Compliance achieved after a 1:10 reverse stock split effective June 20, 2025.","The matter is now closed by Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159160,"accession_number":"0001213900-25-059303","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"FDA issues Complete Response Letter for Unicycive's oxylanthanum carbonate NDA; company plans Type A meeting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CRL cites deficiencies at third-party manufacturing vendor unrelated to OLC drug; no clinical or safety concerns.","Second manufacturing vendor already produced OLC drug product; may resolve CMC issues identified in CRL.","Unicycive plans to immediately request a Type A meeting with FDA to align on next steps.","Preliminary unaudited cash ~$20.7M as of June 30, 2025; cash runway expected into H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159159,"accession_number":"0001213900-25-056188","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Unicycive Therapeutics effects 1-for-10 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-10 ratio effective June 18, 2025; begins trading split-adjusted June 20, 2025.","Reduces outstanding shares from ~126.4M to ~12.6M; no fractional shares (rounded up).","CUSIP changes to 90466Y 202; symbol remains UNCY.","Board authorized reverse split on June 9, 2025; split intended to meet $1.00 minimum bid price for Nasdaq listing.","Proportional adjustments to stock options, warrants, and preferred stock conversion prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159158,"accession_number":"0001213900-25-052824","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Unicycive FDA update: cGMP deficiencies at OLC manufacturing subcontractor; PDUFA June 28","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA identified cGMP deficiencies at a third-party manufacturing subcontractor (not drug substance vendor) for oxylanthanum carbonate.","Label discussions precluded due to deficiencies; company has responded to all FDA information requests.","Final FDA decision expected by PDUFA action date of June 28, 2025.","Company is working with partners to resolve FDA concerns.","CEO expresses confidence in OLC based on clinical and preclinical data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159157,"accession_number":"0001213900-25-052413","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Unicycive shareholders elect four directors and approve reverse stock split at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four director nominees elected: Dr. Aggarwal, Dr. Gupta, Dr. Laumas, Dr. Kenkare-Mitra.","Ratification of Grassi & Co. as independent auditor approved (87.8M for, 531.6K against).","Reverse stock split proposal approved (78.1M for, 9.6M against, 771.4K abstain).","69.7% of total voting power was represented at the meeting (88.4M of 126.9M votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159156,"accession_number":"0001213900-25-046244","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Unicycive changes annual meeting time to 7:00 a.m. PT on June 9, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Date June 9, 2025 and location (Los Altos, CA) unchanged.","Meeting time moved to 7:00 a.m. Pacific Daylight Time.","Record date April 30, 2025; details at https://annualgeneralmeetings.com/uncy2025.","No other changes to the annual meeting announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159155,"accession_number":"0001213900-25-042967","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Unicycive reports Q1 net income $0.5M, cash $19.8M, OLC PDUFA June 28, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income attributable to common stockholders of $0.5M for Q1 2025, vs net loss of $21.2M in Q1 2024.","Cash and cash equivalents totaled $19.8M as of March 31, 2025.","OLC NDA under FDA review with PDUFA target action date of June 28, 2025; commercial launch preparation ongoing.","R&D expenses fell to $2.2M from $6.8M; G&A rose to $5.8M from $2.4M due to launch prep costs.","Patient survey data presented at NKF and ANNA meetings identified pill burden as primary adherence barrier."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159154,"accession_number":"0001213900-25-031593","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K/A","filed_at":"2025-04-14T23:59:59+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"Unicycive Therapeutics corrects warrant expiration dates via 8-K/A amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filing corrects inadvertent clerical error in Expiration Date on Exhibits 4.2 and 4.3 (Amended Tranche B and C Warrants) from Original 8-K.","No other changes made to Original Filing; all terms of Exchange Agreement and Amended Certificate of Designation remain unchanged.","Original March 2024 event exchanged 43,649,000 Series A-2 Preferred shares for Series A-2 Prime Preferred and amended warrants with reduced share counts and revised exercise price of $1,000.","Corrected exhibits reflect accurate expiration dates; no impact on conversion prices or aggregate exercise amounts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177616,"accession_number":"0001213900-25-026270","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Unicycive reports FY 2024 net loss of $37.8M; OLC NDA under FDA review with PDUFA June 28, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to common stockholders $37.8M or $0.56 per share, vs $31.4M ($1.28) in 2023.","Cash and cash equivalents $26.1M as of Dec 31, 2024; company expects to fund operations into 2026.","R&D expenses rose to $20.0M from $12.9M YoY; G&A expenses $12.1M vs $8.5M.","FDA accepted OLC NDA for hyperphosphatemia; PDUFA target action date June 28, 2025.","Commercial planning underway for anticipated OLC launch in late 2025 if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177615,"accession_number":"0001213900-25-001640","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Unicycive gets Nasdaq extension to July 7, 2025 to meet $1 bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Initial non-compliance notice received July 9, 2024; 180-day cure period ended Jan 6 without compliance.","Nasdaq granted an additional 180 calendar days, until July 7, 2025, to regain $1.00 minimum bid.","Company will monitor bid price and may consider options such as a reverse stock split if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194319,"accession_number":"0001213900-24-097145","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Unicycive Q3 net loss $4.1M; OLC NDA accepted with PDUFA June 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.1M vs $4.4M YoY; cash $32.3M expected to fund into 2026.","FDA accepted OLC NDA for hyperphosphatemia; PDUFA target action date June 28, 2025.","OLC patient survey: 79% preferred OLC over prior therapy; 98% said easy to take.","UNI-494 Phase 1 completed; plans to request FDA meeting by end of 2024.","Added to Russell Microcap Index effective July 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194318,"accession_number":"0001213900-24-096104","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA accepts Unicycive's NDA for Oxylanthanum Carbonate; PDUFA date June 28, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted NDA for OLC to treat hyperphosphatemia in CKD patients on dialysis.","PDUFA target action date set for June 28, 2025; company preparing for commercial launch in H2 2025.","FDA granted a waiver for the NDA application PDUFA fees, saving approximately $4 million.","OLC aims to reduce pill burden vs. current options (up to 12 pills/day); pills are swallowed, not chewed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210659,"accession_number":"0001213900-24-081531","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Unicycive Therapeutics regains compliance with Nasdaq minimum market value requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq confirmed compliance with Listing Rule 5550(b)(2) on Sept 24, 2024 after market value exceeded $35M for 10 consecutive days.","Market value was above $35M from Sept 10 to Sept 23, 2024, regaining compliance.","Company had previously received a non-compliance notice on July 11, 2024 for failing to meet the minimum market value.","Removes immediate risk of delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210658,"accession_number":"0001213900-24-068597","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Unicycive Q2 net income $3.0M; OLC NDA on track for August 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["OLC pivotal trial: 1.4% discontinuation rate (evaluable) for treatment-related AEs; no SAEs.","Patient survey: 79% preferred OLC, 98% found it easy to take, 89% satisfied.","UNI-494 Phase 1 enrollment completed; data expected Q3 2024; new patent granted until 2040.","R&D expenses $4.9M (up $2.6M YoY); cash $41.8M, sufficient into 2026.","Diluted EPS loss $0.15; basic EPS $0.08 due to warrant liability fair value change."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210657,"accession_number":"0001213900-24-061355","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Unicycive receives Nasdaq deficiency notices for bid price and market value","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On July 9, 2024, Nasdaq notified Unicycive that stock bid price closed below $1.00 for 30 consecutive days, violating Listing Rule 5550(a)(2).","On July 11, 2024, Nasdaq notified that Market Value of Listed Securities was below $35M for 30 consecutive days, violating Rule 5550(b)(2).","Company has 180 calendar days (until Jan 6/7, 2025) to regain compliance for each deficiency by meeting thresholds for 10 consecutive business days.","If non-compliant after grace period, Nasdaq may delist; company can appeal. No assurance of maintaining listing.","Stock continues trading on Nasdaq Capital Market under UNCY; company monitoring and evaluating options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210656,"accession_number":"0001213900-24-061354","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Unicycive Therapeutics receives Nasdaq bid price deficiency notice; 180 days to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on July 9, 2024 for bid price below $1.00 for 30 consecutive business days.","Has until January 6, 2025 to regain compliance by closing at $1.00+ for ten consecutive business days.","Stock continues trading on Nasdaq Capital Market under symbol UNCY; company may consider options.","If not compliant by Jan 6, 2025, may qualify for second 180-day period or face delisting with appeal rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210655,"accession_number":"0001213900-24-058621","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Unicycive amends OLC manufacturing deal with Shilpa, secures binding purchase order","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Binding purchase order for OLC tablets; delivery by June 30, 2025.","Additional OLC tablet orders required between Dec 31, 2025 and June 30, 2026.","Company to provide funding to Shilpa for a new manufacturing line.","Initial term extended to 8th anniversary of FDA approval of OLC NDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229022,"accession_number":"0001213900-24-056224","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Unicycive Therapeutics doubles authorized common stock to 400M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved increase from 200M to 400M shares on June 20, 2024.","Certificate of Amendment filed with Delaware on June 21, 2024, effective immediately.","No specific use of the additional shares or dilution impact disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229021,"accession_number":"0001213900-24-055436","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Unicycive OLC pivotal trial meets primary endpoint; NDA submission planned Q3 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint achieved: only 1.4% treatment-related discontinuation in evaluable population (n=71), vs 14% for Fosrenol.","Secondary safety endpoint: no treatment-related SAEs; most AEs mild-moderate; diarrhea (9%) and vomiting (6%) most common.","After washout, 90% of safety population (77/86) achieved phosphate ≤5.5 mg/dL at end of titration with OLC.","NDA submission via 505(b)(2) pathway anticipated Q3 2024, supported by bioequivalence and preclinical data.","Study enrolled 106 patients; OLC demonstrated tolerability at clinically effective doses (up to 3000 mg/day)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229020,"accession_number":"0001213900-24-054279","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Unicycive stockholders approve Nasdaq 20% issuance and share increase at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All four director nominees elected: Dr. Shalabh Gupta, Dr. Sandeep Laumas, Dr. Gaurav Aggarwal, Dr. Saraswati Kenkare-Mitra.","Appointment of Grassi & Co. CPAs as independent auditor for FY2024 ratified with 35,666,926 votes for.","Nasdaq 20% Issuance Proposal approved with 26,794,427 votes for, 262,272 against.","Authorized Share Increase Proposal approved with 34,150,333 votes for, 1,735,688 against.","Second amendment and restatement of 2021 Omnibus Equity Incentive Plan approved with 26,540,959 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229019,"accession_number":"0001213900-24-042338","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Unicycive Q1 net loss $21.2M ($0.61/sh); OLC pivotal topline due Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.2M ($0.61/sh) vs $14.8M ($0.97) in Q1 2023; R&D expenses rose to $6.8M from $3.0M.","Cash $48.9M at March 31, 2024; funded operations expected into 2026.","Topline data from OLC pivotal trial in CKD on dialysis expected in Q2 2024.","UNI-494 Phase 1 MAD portion ongoing; FDA orphan drug designation for prevention of DGF in kidney transplant.","Completed $50M private placement with healthcare institutional investors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247632,"accession_number":"0001213900-24-027373","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Unicycive reports FY2023 net loss of $31.4M; OLC topline data expected Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 net loss $31.4M ($1.28/share) vs $18.1M ($1.20/share) in FY2022.","Cash $9.7M at Dec 31, 2023; subsequent $50M private placement extends runway into 2026.","Pivotal OLC trial enrollment completed; topline data expected in Q2 2024.","UNI-494 granted FDA Orphan Drug Designation for delayed graft function; Phase 1 SAD complete, MAD ongoing.","R&D expenses $12.9M, G&A $8.5M; licensing revenue $0.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247631,"accession_number":"0001213900-24-022623","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["1.01","3.02","5.03","8.01","9.01"],"status":"ready","headline":"Unicycive raises $50M in private placement of Series B Convertible Preferred Stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$50M gross proceeds from sale of 50,000 Series B shares at $1,000 each; close expected March 18, 2024.","Conversion price set at $1.00 per share; conversion contingent on stockholder approval of share issuance.","Annual dividend of 8%, increasing to 14% if stockholder approval is not obtained at first meeting.","Led by new investors Octagon Capital and Great Point Partners, with participation from Logos Capital, Nantahala Capital, SilverArc Capital, Velan Capital, Vivo Capital, and Walleye Capital.","Proceeds to support pivotal trial of Oxylanthanum Carbonate (OLC) and general working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247630,"accession_number":"0001213900-24-022600","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"Unicycive exchanges 43.6M Series A-2 preferred shares for 21,388 new preferred, amends warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged 43,649,000 Series A-2 Preferred shares for 21,388.01 shares of new Series A-2 Prime Preferred.","Amended Tranche A, B, C warrants; reduced shares issuable, set exercise price at $1,000 per share.","New preferred series have conversion prices from $0.49 to $0.74 per share of common stock.","All prior Series A-1 through A-5 preferred eliminated via Certificates of Elimination.","Exchange treated as tax-free recapitalization under Sections 368(a)(1)(e) and/or 1036 of the Code."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247629,"accession_number":"0001213900-24-015753","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Unicycive regains compliance with Nasdaq minimum market value and bid price rules","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Feb 21, 2024, Nasdaq notified Unicycive that it regained compliance with the $35M minimum market value and $1.00 minimum bid price requirements.","Non-compliance notices were originally received on Sept 19, 2023, for both Nasdaq Listing Rules 5550(b)(2) and 5550(a)(2).","The compliance matters are now closed with no further action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265088,"accession_number":"0001213900-23-087029","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Unicycive reports Q3 net loss of $4.4M; FDA alignment on OLC NDA path","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.4M ($0.13/share) vs $5.6M ($0.37/share) in Q3 2022; R&D expenses $3.4M, down from $4.8M.","Reached agreement with FDA on data package for OLC NDA; pivotal trial of 60 patients expected by year-end, topline data mid-2024.","Cash $14.3M expected to fund into H2 2024 including pivotal trial and topline data.","Appointed Dr. Sara Kenkare-Mitra to Board of Directors; she has experience with 100+ IND filings and 11 drug approvals.","No licensing revenue in Q3 vs $1.0M in prior period due to 2022 upfront payment."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":675000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265087,"accession_number":"0001013762-23-005659","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2023-10-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Unicycive reaches FDA alignment on NDA path for OLC; pivotal trial to start by end of 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed on full NDA package requirements: clinical, preclinical, and CMC data for Oxylanthanum Carbonate (OLC).","Pivotal open-label trial to enroll 60 CKD dialysis patients; 4-week evaluation after dose titration.","Top-line data expected Q2 2024; no statistical analysis required; efficacy referenced from prior bioequivalence study.","Cash of $18.8M as of June 30, 2023 expected to fund trial and operations into H2 2024.","NDA to be filed via 505(b)(2) pathway referencing Fosrenol; only one clinical study required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282294,"accession_number":"0001213900-23-079139","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2023-09-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Unicycive receives Nasdaq deficiency notices for market value <$35M and bid price <$1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Sept 19, 2023, Nasdaq notified UNCY its market value of common stock was below $35M minimum for 30 consecutive business days.","Also on Sept 19, bid price closed below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).","Company has 180 calendar days, until March 18, 2024, to regain compliance for both requirements.","If compliance not regained, common stock may be delisted; Company can appeal to a Hearings Panel.","Company intends to monitor market value and evaluate options to regain compliance, but no assurance given."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282293,"accession_number":"0001213900-23-074164","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2023-09-06T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Unicycive Therapeutics appoints veteran drug developer Sara Kenkare-Mitra to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Sara Kenkare-Mitra, PhD as independent director effective September 6, 2023.","Dr. Kenkare-Mitra is President & Head of R&D at Alector; previously 23 years at Genentech as SVP.","She played key role in >100 IND/CTA filings and 11 drug approvals across multiple diseases.","Her expertise expected to help advance oxylanthanum carbonate toward NDA filing and UNI-494 IND."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282292,"accession_number":"0001213900-23-072838","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2023-08-31T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Unicycive Therapeutics appoints Grassi & Co. as new auditor effective Aug 28, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Grassi & Co. CPAs, P.C. appointed as independent registered public accounting firm on Aug 28, 2023, subject to client acceptance.","Appointment follows resignation of prior auditor Mayer Hoffman McCann P.C., disclosed on July 31, 2023.","No prior consultations with Grassi on accounting principles or audit opinions during 2022 or through June 30, 2023.","No disagreements or reportable events occurred between company and previous auditor.","Audit Committee approved the appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282291,"accession_number":"0001213900-23-067398","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2023-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Unicycive Q2 net loss $4.4M; OLC FDA feedback expected Fall 2023; UNI-494 Phase 1 ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.4M ($0.29/share) in Q2 2023, up from $3.6M ($0.24) in Q2 2022 due to higher R&D and G&A costs.","Cash and equivalents totaled $18.8M as of June 30, 2023.","Positive OLC data published in Am J Nephrol: lowest daily dose volume vs five commercial phosphate binders.","Expects FDA alignment feedback in Fall 2023 for OLC program; NDA submission after that.","UNI-494 Phase 1 trial ongoing in UK; pre-IND meeting with FDA planned by year-end; IND expected in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":675000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282290,"accession_number":"0001213900-23-061295","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2023-07-31T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Auditor Mayer Hoffman McCann resigns as Unicycive's independent auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Auditor MHM resigned effective upon earlier of new auditor engagement, filing of June 2023 Form 10-Q, or Aug 20, 2023.","No report modifications for FY 2022; no disagreements on accounting principles or audit scope during 2022 or through July 25, 2023.","Company previously reported material weakness in internal control over financial reporting as of Dec 31, 2022 due to lack of adequate staffing.","Company is currently interviewing other accounting firms to replace MHM as independent registered public accounting firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282289,"accession_number":"0001213900-23-059806","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Unicycive regains Nasdaq minimum market value compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received non-compliance notice on May 17, 2023 for MVLS below $35M.","MVLS remained above $35M for 10 consecutive business days ending July 24.","Nasdaq confirmed compliance on July 25, 2023.","Delisting risk removed; stock continues trading on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301443,"accession_number":"0001213900-23-053035","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Unicycive receives FDA request for additional data on LDC NDA; timeline extended","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA asked for risk assessment and clinical data to evaluate tolerability of lanthanum dioxycarbonate in dialysis patients.","Pre-NDA meeting revealed quantitative differences in GI adverse findings between LDC and lanthanum carbonate.","Company plans follow-up meeting with FDA and expects further updates in Q3 2023.","Bioequivalence to Fosrenol was previously established in Phase I studies; no GI neoplasms seen in mouse study.","LDC targets hyperphosphatemia in CKD dialysis patients; global market opportunity >$2.5B in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301442,"accession_number":"0001213900-23-051702","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2023-06-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Unicycive shareholders elect all 4 director nominees, approve reverse stock split and equity plan amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors elected: Dr. Shalabh Gupta, Dr. Sandeep Laumas, Dr. John Ryan, Dr. Gaurav Aggarwal.","Ratified Mayer Hoffman McCann as auditor for FY2023 (13,057,585 for, 30,776 against).","Approved Nasdaq 20% issuance proposal (8,129,197 for, 236,958 against).","Approved reverse stock split proposal (12,679,613 for, 412,810 against).","Approved amendment and restatement of 2021 Omnibus Equity Incentive Plan (9,474,374 for, 959,587 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301441,"accession_number":"0001213900-23-042369","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2023-05-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Unicycive receives Nasdaq notice for failure to meet $35M market value requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Unicycive on May 17, 2023 that common stock MV fell below $35M for 30 consecutive business days.","Company has 180 calendar days, until November 13, 2023, to regain compliance.","If compliance not met by deadline, stock may be delisted; company can appeal to a Hearings Panel.","Unicycive will monitor market value and evaluate options; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301440,"accession_number":"0001213900-23-040217","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Unicycive Q1 net loss $14.6M ($0.97/sh) vs $3.5M loss YoY; cash $24.3M from $30M upfront financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.6M ($0.97/sh) compared to $3.5M ($0.24/sh) in Q1 2022; includes $10.4M change in warrant liability.","Licensing revenue $0.7M from Lotus Pharma agreement for Renazorb in South Korea signed February 2023.","Cash and cash equivalents $24.3M (Dec 2022: $0.5M) after $30M upfront from up to $130M private placement.","Plans to file NDA for Renazorb by Q3 2023 with potential approval and launch in 2024.","UNI-494 Phase 1 first cohort enrolled; plans to file IND in 2024 for Phase 2 trial in AKI."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":675000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301439,"accession_number":"0001213900-23-028383","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2023-04-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Unicycive Therapeutics amends reverse stock split ratio range to 1-for-2 to 1-for-20","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 1 changes the reverse stock split ratio range from 1-for-10–1-for-20 to 1-for-2–1-for-20.","The amendment modifies Section 4.16(iii) of the Securities Purchase Agreement dated March 3, 2023.","Company will seek stockholder approval of the revised reverse split range at the upcoming annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321261,"accession_number":"0001213900-23-024969","cik":1766140,"company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Unicycive reports 2022 net loss of $18.1M, cash $0.5M; closes $30M fundraise; NDA on track for mid-2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for 2022 was $18.1M ($1.20/sh) vs $10.0M ($0.86/sh) in 2021.","Cash and equivalents $0.5M at Dec 31, 2022; closed $30M private placement with up to $130M total.","Renazorb pivotal BE study met primary endpoint; NDA submission on track for mid-2023.","Exclusive license with Lotus Pharma for Renazorb in South Korea.","R&D expenses $12.4M (up 103% YoY) driven by $6.5M in development services."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":675000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":206390000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-03-31T23:59:59+00:00|321261"}